ST
$27.08
+2.26
(+9.11%)
As of Oct 20, 2026, 3:07 PM EDT · cached
Price history
Stoke Therapeutics Inc (STOK) is trading up at $27.08 (+9.11%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: June 19, 2019 · $18.00 offering · NASDAQ · View IPO details →
Stoke Therapeutics Inc revenue & net income history (FY2018–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | $12.4M | $8.78M | $36.6M | $184.4M |
| Growth (year over year) | — | — | — | — | — | −29.2% | +316.3% | +404.5% |
| Operating income | −$12.8M | −$35.7M | −$53.0M | −$86.1M | −$104.4M | −$114.8M | −$101.4M | −$20.6M |
| Operating margin | — | — | — | — | −841.2% | −1307.2% | −277.3% | −11.2% |
| Net income | −$12.5M | −$32.3M | −$52.2M | −$85.8M | −$101.1M | −$104.7M | −$89.0M | −$6.88M |
| Net margin | — | — | — | — | −814.7% | −1192.5% | −243.4% | −3.7% |
| EPS (diluted) | −$39.71 | −$4.05 | −$3.51 | −$3.51 | −$2.60 | −$2.38 | −$1.65 | −$0.12 |
| Balance sheet | ||||||||
| Cash and equivalents | $105.4M | $222.5M | $287.3M | $144.9M | $113.6M | $191.4M | $128.0M | $84.2M |
| Total assets | $107.5M | $228.8M | $297.9M | $238.9M | $256.1M | $228.3M | $271.6M | $418.4M |
| Total liabilities | $2.47M | $4.32M | $11.8M | $21.1M | $71.2M | $68.8M | $42.5M | $66.0M |
| Shareholders' equity | $105.1M | $224.4M | $286.1M | $217.8M | $184.8M | $159.6M | $229.0M | $352.5M |
| Cash flow | ||||||||
| Operating cash flow | −$11.0M | −$31.1M | −$42.2M | −$66.9M | −$31.9M | −$81.1M | −$86.9M | $45.6M |
| Capital expenditure | $935.0K | $1.64M | $1.05M | $1.20M | $3.96M | $1.62M | $203.0K | $670.0K |
| Free cash flow | −$11.9M | −$32.7M | −$43.3M | −$68.1M | −$35.8M | −$82.7M | −$87.1M | $44.9M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.89M | — | $158.6M | $13.8M | $10.6M | — | $6.23M | $9.32M |
| Growth (year over year) | +47.9% | — | +3661.1% | +186.0% | +117.2% | — | −96.1% | −32.5% |
| Operating income | −$30.0M | — | $111.2M | −$27.3M | −$43.1M | — | −$53.4M | −$65.4M |
| Operating margin | −613.1% | — | 70.2% | −197.6% | −405.3% | — | −857.6% | −701.7% |
| Net income | −$26.4M | — | $112.9M | −$23.5M | −$38.3M | — | −$50.0M | −$61.6M |
| Net margin | −540.0% | — | 71.2% | −170.0% | −360.7% | — | −802.7% | −660.8% |
| EPS (diluted) | −$0.47 | — | $1.90 | −$0.40 | −$0.65 | — | −$0.79 | −$0.93 |
| Balance sheet | ||||||||
| Cash and equivalents | $150.0M | $128.0M | $274.8M | $101.5M | $83.4M | $84.2M | $155.7M | $110.0M |
| Total assets | $293.3M | $271.6M | $406.9M | $384.5M | $360.3M | $418.4M | $443.3M | $394.0M |
| Total liabilities | $61.2M | $42.5M | $56.8M | $49.6M | $52.2M | $66.0M | $48.4M | $48.4M |
| Shareholders' equity | $232.1M | $229.0M | $350.1M | $334.9M | $308.1M | $352.5M | $394.9M | $345.5M |
| Cash flow | ||||||||
| Operating cash flow | −$21.6M | — | $131.8M | −$25.4M | −$30.4M | — | −$60.6M | −$56.6M |
| Capital expenditure | $103.0K | — | $152.0K | $154.0K | $132.0K | — | $353.0K | $1.98M |
| Free cash flow | −$21.7M | — | $131.7M | −$25.6M | −$30.5M | — | −$60.9M | −$58.6M |
From Stoke Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →
About Stoke Therapeutics Inc
- Headquarters
- Bedford, Massachusetts From SEC filings, Oct 2026
Recent News (5)
-
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock
-
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock
-
Stoke Therapeutics presents data on ADOA treatment STK-002
Stoke Therapeutics presents data on ADOA treatment STK-002
-
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with…
-
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) –4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International